Considerations on discontinuing natalizumab for the treatment of multiple sclerosis.
نویسندگان
چکیده
published by admin on Mon, 08/19/2013 3:11pm Title Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Publication Type Journal Article Year of Publication 2010 Authors Berger, JR, Centonze, D, Comi, G, Confavreux, C, Cutter, G, Giovannoni, G, Gold, R, Hartung, H-P, Lublin, F, Miravalle, A, Montalban, X, O'Connor, P, Olsson, T, Polman, CH, Stüve, O, Wolinsky, JS, Ziemssen, T Journal Ann Neurol Volume 68 Issue 3 Pagination 409-11 Date Published 2010 Sep ISSN 1531-8249
منابع مشابه
The use of natalizumab for multiple sclerosis
Natalizumab is a monoclonal antibody that acts as an α4 integrin antagonist to prevent leukocyte trafficking into the central nervous system. It is US Food and Drug Administration (FDA) approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). Natalizumab demonstrated high efficacy in Phase III trials by reducing the annualized relapse rate, preventing multiple sclerosis (MS)...
متن کاملNatalizumab treatment for multiple sclerosis: updates and considerations for safer treatment in JCV positive patients.
Natalizumab is currently one of the best options for treatment of patients with Multiple Sclerosis who have failed traditional prior therapies. However, prolonged use, prior immunosuppressive therapy and anti-JCV antibody status have been associated with increased risk of developing progressive multifocal leukoencephalopathy (PML). The evaluation of these conditions has been used to estimate ri...
متن کاملAn update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations
In the context of an increasing repertoire of multiple sclerosis (MS) therapeutics, choosing the appropriate treatment for an individual patient is becoming increasingly challenging. Natalizumab, a humanized monoclonal antibody directed against alpha4beta1 integrin, has proven short-term and long-term efficacies in terms of relapse rate reduction, prevention of disability progression, and reduc...
متن کاملMultiple Sclerosis: Immunopathology and Treatment Update
The treatment of multiple sclerosis (MS) has changed over the last 20 years. All immunotherapeutic drugs target relapsing remitting MS (RRMS) and it still remains a medical challenge in MS to develop a treatment for progressive forms. The most common injectable disease-modifying therapies in RRMS include β-interferons 1a or 1b and glatiramer acetate. However, one of the major challenges of inje...
متن کاملIs natalizumab a breakthrough in the treatment of multiple sclerosis?
In patients with either relapsing-remitting or secondary-progressive multiple sclerosis, there were fewer new lesions/patient with natalizumab (0.7 and 1.1 with natalizumab 3 and 6 mg/kg every 28 days, respectively) than in the placebo group (9.6 new lesions/patient) over 6 months. There were also fewer relapses in the natalizumab groups than the placebo group. However, there were no changes in...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Annals of neurology
دوره 68 3 شماره
صفحات -
تاریخ انتشار 2010